Association Between Reconstruction Technique and Clinical Outcomes in Advanced Gastric Cancer Patients Undergoing Proximal Gastrectomy
2024

Surgery Techniques for Advanced Gastric Cancer

Sample size: 60 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sędłak Katarzyna, Rawicz-Pruszyński Karol, Pelc Zuzanna, Mlak Radosław, Gęca Katarzyna, Skórzewska Magdalena, Zinkiewicz Krzysztof, Chawrylak Katarzyna, Polkowski Wojciech P.

Primary Institution: Medical University of Lublin

Hypothesis

Is double-tract reconstruction (DTR) more effective than esophagogastrostomy with partial neo-fundoplication (EGF) in achieving optimal surgical outcomes after proximal gastrectomy?

Conclusion

DTR is more likely to achieve optimal short-term surgical outcomes compared to EGF, but both methods show similar overall survival rates.

Supporting Evidence

  • Patients undergoing DTR were 5.5 times more likely to achieve textbook outcomes compared to those receiving EGF.
  • No significant differences in overall survival were noted between the two reconstruction methods.
  • Patients in the DTR group had a higher median number of lymph nodes retrieved compared to the EGF group.
  • Preoperative chemotherapy was more commonly used in the DTR group, suggesting better overall health.
  • Further randomized controlled trials are needed to confirm these findings.

Takeaway

This study looked at two ways to fix the stomach after surgery for cancer. One way worked better for short-term results, but both ways had similar long-term survival.

Methodology

The study analyzed data from 60 patients who underwent proximal gastrectomy with either DTR or EGF, comparing their surgical outcomes.

Potential Biases

Selection bias may have affected the comparability between the groups due to the non-randomized design.

Limitations

The study's retrospective design and small sample size may limit the generalizability of the findings.

Participant Demographics

Patients included were primarily diagnosed with intestinal type advanced gastric cancer, with 73.3% receiving neoadjuvant chemotherapy.

Statistical Information

P-Value

0.0266

Confidence Interval

95% CI [1.22–26.30]

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/cancers16244282

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication